BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

409 related articles for article (PubMed ID: 26311249)

  • 21. Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts.
    Kitange GJ; Carlson BL; Schroeder MA; Grogan PT; Lamont JD; Decker PA; Wu W; James CD; Sarkaria JN
    Neuro Oncol; 2009 Jun; 11(3):281-91. PubMed ID: 18952979
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MEK-ERK signaling dictates DNA-repair gene MGMT expression and temozolomide resistance of stem-like glioblastoma cells via the MDM2-p53 axis.
    Sato A; Sunayama J; Matsuda K; Seino S; Suzuki K; Watanabe E; Tachibana K; Tomiyama A; Kayama T; Kitanaka C
    Stem Cells; 2011 Dec; 29(12):1942-51. PubMed ID: 21957016
    [TBL] [Abstract][Full Text] [Related]  

  • 23. SNAP reverses temozolomide resistance in human glioblastoma multiforme cells through down-regulation of MGMT.
    Tsai CK; Huang LC; Wu YP; Kan IY; Hueng DY
    FASEB J; 2019 Dec; 33(12):14171-14184. PubMed ID: 31725331
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Resveratrol reverses temozolomide resistance by downregulation of MGMT in T98G glioblastoma cells by the NF-κB-dependent pathway.
    Huang H; Lin H; Zhang X; Li J
    Oncol Rep; 2012 Jun; 27(6):2050-6. PubMed ID: 22426504
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effects of tumor treating fields and temozolomide in MGMT expressing and non-expressing patient-derived glioblastoma cells.
    Clark PA; Gaal JT; Strebe JK; Pasch CA; Deming DA; Kuo JS; Robins HI
    J Clin Neurosci; 2017 Feb; 36():120-124. PubMed ID: 27865821
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Integrative genomic analysis of temozolomide resistance in diffuse large B-cell lymphoma.
    Leshchenko VV; Kuo PY; Jiang Z; Thirukonda VK; Parekh S
    Clin Cancer Res; 2014 Jan; 20(2):382-92. PubMed ID: 24178621
    [TBL] [Abstract][Full Text] [Related]  

  • 27. IDH mutation and MGMT promoter methylation are associated with the pseudoprogression and improved prognosis of glioblastoma multiforme patients who have undergone concurrent and adjuvant temozolomide-based chemoradiotherapy.
    Li H; Li J; Cheng G; Zhang J; Li X
    Clin Neurol Neurosurg; 2016 Dec; 151():31-36. PubMed ID: 27764705
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The impact of sequential vs. combined radiochemotherapy with temozolomide, resection and MGMT promoter hypermethylation on survival of patients with primary glioblastoma--a single centre retrospective study.
    Rapp M; Goeppert M; Felsberg J; Steiger HJ; Sabel M
    Br J Neurosurg; 2013 Aug; 27(4):430-5. PubMed ID: 23418781
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Specificity protein 1-modulated superoxide dismutase 2 enhances temozolomide resistance in glioblastoma, which is independent of O
    Chang KY; Hsu TI; Hsu CC; Tsai SY; Liu JJ; Chou SW; Liu MS; Liou JP; Ko CY; Chen KY; Hung JJ; Chang WC; Chuang CK; Kao TJ; Chuang JY
    Redox Biol; 2017 Oct; 13():655-664. PubMed ID: 28822335
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Temozolomide-induced increase of tumorigenicity can be diminished by targeting of mitochondria in in vitro models of patient individual glioblastoma.
    William D; Walther M; Schneider B; Linnebacher M; Classen CF
    PLoS One; 2018; 13(1):e0191511. PubMed ID: 29352318
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MiR-198 enhances temozolomide sensitivity in glioblastoma by targeting MGMT.
    Nie E; Jin X; Wu W; Yu T; Zhou X; Shi Z; Zhang J; Liu N; You Y
    J Neurooncol; 2017 May; 133(1):59-68. PubMed ID: 28425046
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients.
    Brandes AA; Franceschi E; Tosoni A; Blatt V; Pession A; Tallini G; Bertorelle R; Bartolini S; Calbucci F; Andreoli A; Frezza G; Leonardi M; Spagnolli F; Ermani M
    J Clin Oncol; 2008 May; 26(13):2192-7. PubMed ID: 18445844
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MEX3A Impairs DNA Mismatch Repair Signaling and Mediates Acquired Temozolomide Resistance in Glioblastoma.
    Gan T; Wang Y; Xie M; Wang Q; Zhao S; Wang P; Shi Q; Qian X; Miao F; Shen Z; Nie E
    Cancer Res; 2022 Nov; 82(22):4234-4246. PubMed ID: 36112059
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Minimally cytotoxic doses of temozolomide produce radiosensitization in human glioblastoma cells regardless of MGMT expression.
    Bobola MS; Kolstoe DD; Blank A; Silber JR
    Mol Cancer Ther; 2010 May; 9(5):1208-18. PubMed ID: 20457618
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Silencing SATB1 overcomes temozolomide resistance by downregulating MGMT expression and upregulating SLC22A18 expression in human glioblastoma cells.
    Yang B; Ma YB; Chu SH
    Cancer Gene Ther; 2018 Dec; 25(11-12):309-316. PubMed ID: 30140041
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular mechanisms of temozolomide resistance in glioblastoma multiforme.
    Johannessen TC; Bjerkvig R
    Expert Rev Anticancer Ther; 2012 May; 12(5):635-42. PubMed ID: 22594898
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Temozolomide Induces the Acquisition of Invasive Phenotype by O6-Methylguanine-DNA Methyltransferase (MGMT)
    Kochanowski P; Catapano J; Pudełek M; Wróbel T; Madeja Z; Ryszawy D; Czyż J
    Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33923767
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Distinct molecular mechanisms of acquired resistance to temozolomide in glioblastoma cells.
    Happold C; Roth P; Wick W; Schmidt N; Florea AM; Silginer M; Reifenberger G; Weller M
    J Neurochem; 2012 Jul; 122(2):444-55. PubMed ID: 22564186
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Differential Characterization of Temozolomide-Resistant Human Glioma Cells.
    Lai SW; Huang BR; Liu YS; Lin HY; Chen CC; Tsai CF; Lu DY; Lin C
    Int J Mol Sci; 2018 Jan; 19(1):. PubMed ID: 29301329
    [TBL] [Abstract][Full Text] [Related]  

  • 40. ATP binding cassette (ABC) transporters: expression and clinical value in glioblastoma.
    Dréan A; Rosenberg S; Lejeune FX; Goli L; Nadaradjane AA; Guehennec J; Schmitt C; Verreault M; Bielle F; Mokhtari K; Sanson M; Carpentier A; Delattre JY; Idbaih A
    J Neurooncol; 2018 Jul; 138(3):479-486. PubMed ID: 29520610
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.